A549 cell

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Retrieved on: 
Wednesday, January 11, 2023
Potyvirus, Therapy, CMC, Immunotherapy, A549, Valo, Vaccine, Infection, A549 cell, Patient, Cancer, Doe, CDMO, GMP

HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.

Key Points: 
  • HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.
  • ValoTx’s VALO-D102 oncolytic adenovirus is a fundamental component of the company’s proprietary PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform.
  • Exothera brings expertise in adenovector and A549 cells with a deep knowledge of state-of-the-art manufacturing technology and DoE-based development tools.
  • This important work with Exothera will enable us to develop a large-scale manufacturing process for VALO-D102 to support our future clinical development plans and pave the way for future commercial-scale manufacturing.”

TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections

Retrieved on: 
Tuesday, December 14, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Method, Forward-looking statement, U.S. Securities and Exchange Commission, LinkedIn, A549 cell, Severe acute respiratory syndrome coronavirus 2, 1836 U.S. Patent Office fire, Uncertainty, RNA transfection, Company, United States Patent and Trademark Office, Membrane protein, Hematological Cancer Research Investment and Education Act, Liver disease, Nasdaq, COVID-19, Cancer, Breast, Annual report, Toxicology, Prostate, Risk, Private Securities Litigation Reform Act, Research, Safety, Patient, Knowledge, Disease, Steroid, SARS, Virus, Twitter, Alpha, Sarcoma, Patent, Pharmaceutical industry, Vaccine, Omicron, TYME, Evotec, Delta, A549, Facebook, TYME Technologies, Inc., TYME-19, TYME TECHNOLOGIES, INC., TYME-19

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections.

Key Points: 
  • TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections.
  • The Company has retained virology experts at Evotec to assess the mechanisms of TYME-19.
  • In this initial preclinical study, TYME-19 was tested post-COVID-19 infection in human lung epithelial cells (A549 cells), examining changes in viral mRNA levels.
  • At certain doses, viral mRNA inhibition of up to 90% was observed with TYME-19 treatment after 72 hours of exposure.

Over 100 Inhouse Validated Xenograft Models for Preclinical Testing by Altogen Labs

Retrieved on: 
Wednesday, May 22, 2019
Medical specialties, Medicine, Branches of biology, Cancer research, Patient derived xenograft, Xenotransplantation, A549 cell, PDX

AUSTIN, Texas, May 22, 2019 /PRNewswire/ -- Altogen Labs , a GLP-compliant preclinical research company, announced addition of seven inhouse validated xenograft models ( A549 , BT474 , HUH7 , MDA-MB-231 , MKN-74 , N87 , and PC-3 ).

Key Points: 
  • AUSTIN, Texas, May 22, 2019 /PRNewswire/ -- Altogen Labs , a GLP-compliant preclinical research company, announced addition of seven inhouse validated xenograft models ( A549 , BT474 , HUH7 , MDA-MB-231 , MKN-74 , N87 , and PC-3 ).
  • This will make a total of 115 CDX xenograft models, 30 PDX xenograft models, and over 40 syngeneic xenograft models provided by Altogen Labs.
  • Xenograft models used in preclinical oncology research for novel cancer treatment safety and efficacy investigations.
  • Altogen Labs offers a selection of over 100 in-house validated xenograft models of CDX (cell line derived xenografts) and the option for PDX (patient derived xenograft) studies and 40 syngeneic xenograft models.